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Omics Sciences
Introduction
Biotechnology is arguably the original multidisciplinary science, utilising living systems 
or their products to provide goods and services. The burgeoning biotechnology sector has 
expanded to include new ways to accumulate and analyse information about the struc-
ture and function of the genomes that together with environment, determine all aspects 
of growth and development, through genomics.   Major advances have also been made 
in genome editing, which allows novel and precise mechanisms to modify the structure 
of genomes. Most recently, the first examples of three-parent babies have added to the 
utility of biotechnology. These advances provide unprecedented opportunities to increase 
understanding of genome structure, epigenetics and gene transfer. Future applications 
of biotechnology will increasingly build upon genomics and genome editing progress, 
to span sub-sectors, requiring complex contributions from areas as diverse as microbial 
genetics, to bioinformatics, and from agricultural science to human reproductive physi-
ology. 
 
The burgeoning genomics revolution
Genomics sciences have become one of the biggest growth areas in biotechnology, by 
studying the nucleic acids (DNA and RNA) that drive gene expression for all organisms. 
Since the advent of the Human Genome Project in 1990, tasked with mapping and se-
quencing the 3 Bnbp that make up the haploid human chromosome set, a series of key 
genomics events have taken place (Table 1).  
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Abstract
Genomics, the study of genes, their functions and related techniques has become a crucial science for developing understand-
ing of life processes and how they evolve.  Since the advent of the human genome project, huge strides have been made in de-
veloping understanding of DNA and RNA sequence information and how it can be put to good use in the biotechnology sector.  
Newly derived sequencing and bioinformatics tools have added to the torrent of new insights gained, so that ‘sequence once 
and query often’ type DNA apps are now becoming reality. Genome editing, using tools such as CRISPR/Cas9 nuclease or Cpf1 
nuclease, provide rapid methods for inserting, deleting or modifying DNA sequences in highly precise ways, in virtually any 
animal, plant or microbial system.  Recent international discussions have considered human germline gene editing, amongst 
other aspects of this technology.  Whether or not gene edited plants will be considered as genetically modified remains an 
important question. This will determine the regulatory processes adopted by different groups of nations and applicability to 
feeding the world’s ever growing population.  Questions surrounding the intellectual property rights associated with gene edit-
ing must also be resolved.  Mitochondrial replacement therapy leading to ‘3-Parent Babies’ has been successfully carried out in 
Mexico, by an international team, to correct mother to child mitochondrial disease transmission.  The UK has become the first 
country to legally allow ‘cautious use’ of mitochondrial donation in treatment.  Genomics and genome editing will continue 
to advance what can be achieved technically, whilst society determines whether or not what can be done should be applied.    
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Table 1. Genomics revolution key events
Date Event
1990 $2.7 Bn mapping and sequencing Human Genome Project launched
1995 1st Microbial genome sequenced: Haemophilus influenza (1)
1998 1st Multi-cellular organism genome sequenced: Caenorhabditis elegans (2)
1999 Human Chromosome 22 sequenced
2001 Draft version Human Genome published, jointly by Human Genome Project and Celera (3,4)
2004 ‘Finished’ version Human Genome published (5)
2007 23andMe offer direct to consumer genetic testing
2014 $1000 Human genome sequencing commercially available, using Illumina HiSeq X Ten Sequencer for 30x coverage
2015 Personal Genome Project and Veritas Genetics launch $999 full-genome sequencing and interpretation service (6)






































Figure 1. Approaches to human genome sequencing. Source: National Human Genome Research Institute.
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The pace of technological advances in genomics, and the de-
velopment of bioinformatics tools to analyse DNA sequences 
have substantially reduced costs, whilst increasing capacity and 
throughput.  Next Generation Sequencing (NGS) platforms 
typically use massive parallel sequencing of clonally amplified 
or single DNA molecules spatially separated in a flow cell. Ad-
vances in speed, read length and throughput, and the availabil-
ity of ‘reference genome’ sequences to which millions of reads 
can be aligned (Fig. 1) have contributed to dramatic reductions 
in the cost of genomic sequencing. 
 The vast majority of whole genome DNA sequences iden-
tified now are in ‘draft’ form, with >90% genome coverage and 
99.9% accuracy.  ‘Finished’ DNA sequences, with >95% cover-
age and 99.9% accuracy remain much more expensive to pro-
duce, because of the levels of analysis and curation involved, 
especially with complex genomes (Table 2).   
Together, these advances have paved the way for the devel-
opment of a large number of novel NGS applications in basic 
science as well as in translational research areas such as clinical 
diagnostics, forensic science and agrigenomics. The MinION 
from Oxford Nanopore Technologies (ONT) is the only hand-
held real-time DNA sequencer currently available. Unlike oth-
er platforms, nanopore sequencers do not monitor incorpo-
rations or hybridizations of nucleotides guided by a template 
DNA strand. Whereas other platforms use a secondary signal 
such as light, colour or pH, nanopore sequencers directly de-
tect the DNA composition of a native single stranded DNA 
molecule. DNA is passed through a protein pore as current is 
passed through the pore. As the DNA translocates due to the 
action of a secondary motor protein, a voltage block occurs. 
This modulates the current passing through the pore (7). Trac-
ing changes in these charges through time generates squiggle 
space, with voltage shifts characteristic of the particular DNA 
sequence in the pore, which can then be interpreted as a k-mer. 
Rather than having 1–4 possible signals, the instrument has 
more than 1,000, one for each possible k-mer, especially when 
modified bases present on native DNA are taken into account. 
The MK1 MinION flow cell structure is composed of an appli-
cation-specific integrated circuit (ASIC) chip with 512 individ-
ual channels that are capable of sequencing at ~70 bp/second, 
with an expected increase to 500bp/second projected by 2017. 
The upcoming PromethION instrument is intended to provide 
an ultra-high-throughput platform reported to include 48 indi-
vidual flow cells, each with 3,000 pores running at 500 bp/sec-
ond. This equates to ~2–4Tb for a 2-day run on a fully loaded 
device, placing this instrument in potential competition with 
Illumina’s HiSeq X-Ten system. Similar to the circular template 
used by  Pacific Biosciences, which uses single molecule, re-
al-time (SMRT) consensus sequencing (8), the ONT MinION 
uses a leader–hairpin library structure. This allows the forward 
DNA strand to pass through the pore, followed by a hair-
pin that links the two strands, and finally the reverse strand. 
This generates 1D and 2D reads in which both ‘1D’ strands 
can be aligned to create a consensus sequence ‘2D’ read. En-
hanced nanopore sequencing approaches, such as the Roche 
Genia system, and the recently announced Illumina Firefly, 
with its one-channel complementary metal-oxide-semicon-
ductor (CMOS) technology, point the way to further advanc-
es through superior performance, cost and time savings for 
large scale and clinical applications. NanoString Technologies’ 
enzyme-free hybridization method, Bio-Rad’s GnuBio using 
a fluorescence resonance energy transfer (FRET)-based ap-
proach, and the imaging based Electron Optica which uses an 
electron microscope-based system all aim to further enhance 
sequencing through unique technologies. These existing and 
forthcoming genomic sequencing tools have the potential to 
allow for revolutionary science, including direct sequencing 
of RNA or proteins, real-time genomic pathogen monitoring 
or precision medicine based on personal genome sequencing. 
Further cost savings are achievable by whole exome sequenc-
ing, concentrating only on coding regions, or exons, within ge-
nomes.  Whereas draft human genomic sequencing can now be 
obtained for around $1000 including interpretation via Face-
Time (6,9), whole exome sequencing, which is on a smaller 
scale, may soon cost as little as $100-500.  Tumbling prices for 
sequencing services, allied to major imperatives to see genomic 
sequencing transferred to the clinical setting means that the age 
of personalised genomics is now upon us.  These developments 
have also spawned ‘Consumer Genomics’ in which individuals 
can send off DNA from a single saliva swab for sequencing and 
access a range of analytical services, through the equivalent of 
‘DNA App’ stores.  The resulting information can be stored and 
accessed by any application throughout the life of an individ-
ual.    Examples of ‘Consumer Genomics’ approaches include 
analysing the ancestry of your DNA, costing from as little as 
$100 using 700,000 genetic markers, mapping to 26 ethnic re-
gions globally (10) and the series of health and nutrition related 
screens available from 23andMe (Table 3) for $165. 
Providers of consumer genomics tests emphasise that re-
sults are informational, rather than predictive of diagnoses, or 
Table 2. Genomic complexity
Organism Genome size (n) Genes
Escherichia coli 4.6 Mbp 4,377
Caenorhabditis elegans 100.3 Mbp 21,733
Homo sapiens 3.3 Bnbp ~21,000
Pinus taeda (Loblolly pine) 23.2 Bnbp ~50,000
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guarantees of ancestral lineages, despite being able to apportion 
components of DNA heritage to different racial and ethnic or-
igins. A glimpse of the potential value of this approach comes 
from drug response analyses, of pharmacogenomic relevance, 
where for example, 15% of US citizens fail to respond to the 
widely prescribed clopidrogel (Plavix®) being unable to metab-
olise the pro-drug form into an active form used to prevent 
heart attacks and strokes.  For a drug with global sales which 
reached a high of $9.9Bn in 2011, this represents a huge wasted 
resource, both in financial and risk terms, leading to increased 
numbers of heart attacks and strokes amongst unidentified 
non-responders (11), for which the Cytochrome P450 variant 
CYP 2C19 is a reliable indicator (12).  
‘DNA App Store’ type applications of consumer genomics 
will allow digitised genomic information to be accessed by any 
interested software developer, using a ‘sequence once, query of-
ten’ model (9).  Low cost DNA Apps will undoubtedly emerge 
for both Apple and Android platforms. Two of the earliest de-
velopers of DNA App store prototypes are Helix, with substan-
tial support from Illumina, and Veritas Genetics. Helix propos-
es to eventually drive down the cost of exome sequencing still 
further, to as little as $100, whilst warehousing genomic data 
for paid access by individuals or other app developers, such 
as Good Start Genetics, who offer EmbryVu pre-implantation 
and GeneVu (with Roche) gene carrier screening tests, sup-
plemented by access to genetic counsellors (13). Other com-
panies have invested in corporate genomic profiling, including 
Aetna/Newtopia who have combined limited genetic testing 
with psychosocial assessments to reduce risk of metabolic syn-
drome amongst employees (14), and Pathway Genomics, who 
have launched PathwayFit®, a $599 testing service generating 
personal nutrigenomic reports on >80 gene variants associated 
with aspects of diet, nutrition, exercise and metabolic health 
advice (15). Working with IBM Watson, Pathway have devel-
oped smartphone and web based apps in the United States, 
combining personal genomic data with artificial intelligence 
and deep learning tools to provide individualised strategies and 
recommendations towards optimal health. ‘DNA App Store’ 
type initiatives will undoubtedly drive down initial costs to in-
dividuals, making personalised genomics much more afford-
able, on a pay as you go basis for future screening (9). 
Genomics projects are taking place on increasingly large 
scales, such as the Personal Genome Project, in collaboration 
with Veritas Genetics, and in the United Kingdom, through the 
100,000 Genomes Project, led by National Health Service En-
gland.  This aims to sequence 100,000 whole patient genomes 
from sufferers of 100 rare diseases and seven different types 
of cancer, within three years. >80% of rare diseases, defined 
as occurring in less than 1 in 2,000 of the population, have a 
genomic basis (16).  By 5 December, 2016 16,171 whole ge-
nomes had been sequenced.  This project involves 13 ‘Genomic 
Medical Centres’  and 85 NHS Trusts, comprising 1,500 staff 
and is linked to 2,500 researchers worldwide. A key feature is 
the involvement of Genomics England Clinical Interpretation 
Partnerships, enabling clinicians, academics, and researchers 
to focus on a single disease or condition and analyse patient 
and familial genomic data through a series of dedicated ‘Panel 
Apps’. The scale of this undertaking and the new technologi-
cal solutions being developed within it have attracted several 
high profile commercial partners, such as  Illumina for bio-
informatics analysis including sequencing, data storage and 
interpretation. Twelve commercial pharma, biotech and di-
agnostics partners have come together through the Genom-
ics Expert Network for Enterprises (GENE) Consortium to 
be able to use 5,000 whole genome sequences and participant 
health information on an annual subscription basis, costing in 
excess of £600,000 per company (17). This will lead to signif-
icant job creation opportunities, through drug development, 
new diagnostic tests, treatments, medical devices and ancillary 
services, alongside direct patient benefits. Genomics projects 
large and small give rise to a range of other ‘omics science’ in-
vestigations, from proteomics, to metabolomics and from tran-
scriptomics to the study of interactomics, involving gene-gene, 
protein-protein or protein-ligand interactions, and how micro-
bial populations interact within the gut (18,19).  The can be 
no doubt, however, that the genomics age is here to stay, with 
an ever increasing range of tools, challenges and opportunities 
under development to benefit humankind.  
The inexorable rise of genome editing
Precision editing of genomes using recognition sequences and 
nucleases, has rapidly become a method of choice for altering 
any gene, in almost any organism (20). Four principle meth-
odologies are in use, Zinc Finger Nucleases (ZFN), Transcrip-
tion Activator-Like Effector Nucleases (TALENS), Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR)/
Cas 9 Nuclease and the use of Cpf1 as an alternative to Cas 9 
nuclease, described in Table 4. These systems have evolved in 
Table 3: Aspects of ‘Consumer Genomics’ analysis
Genomic Component Number Available Example
Genetic risk factors 11 Hypertrophic cardiomyopathy (MYBPC3 25 bp deletion)
Inherited conditions 43 Glycogen storage disease 1a/b (G6Pc and SLC37A4 variants)
Non-Health related traits 41 Alcohol flush reaction (ALDH2 variant rs671)
Drug response                                        12 Clopidrogel (Plavix®) efficacy (CYP2C19 variants)
Source: Welcome to You - 23andMe (2016).  http://www.23andMe.co.uk
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bacteria to provide defence through adaptive immunity against 
bacteriophage attack (21), and were initially uncovered in Esch-
erichia coli. Our understanding of them has since benefitted 
from studies in Streptococcus thermophilus, S.  pyogenes, Lacno-
spiraceae and Acidaminococcus.  
CRISPR technologies now overshadow the use of ZFNs or 
TALENS approaches, due to their relative simplicity and target 
specificity. CRISPR has been developed since 2005, when the 
importance of a protospacer adjacent motif (PAM) for target 
recognition became apparent (25).  CRISPR was shown to be 
able to target DNA (26) through the transcription of small, 
spacer sequences, typically derived from previous viral attack 
into CRISPR RNAs (27). Together with Cas9 nuclease, these 
could create double stranded breaks in DNA at precise posi-
tions, 3 nucleotides upstream of the protospacer adjacent motif 
(28). Guide RNA (gRNA) consisting of CRISPR-RNAs (crR-
NA) and trans-activating CRISPR RNA (tracrRNA), pilots Cas 
9 nuclease to targets (29) and functions in other species (30) 
extending the potential utility of CRISPR/Cas9.  The true flex-
ibility of this system became apparent in 2012 when the lab of 
Doudna and Charpentier demonstrated that the crRNA and 
tracrRNA could be combined to make a single synthetic guide 
to target Cas9 nuclease action on any specific sequence (20). 
Double stranded breaks induced by Cas9 are repaired by either 
non-homologous end joining events, or homologous recombi-
nation directed repair (20). This was the beginning of a huge 
expansion in the use of CRISPR/Cas9 for genome editing, al-
lowing deletion, modification or addition of DNA sequences 
with a precision and accuracy previously unheard of (31).  This 
approach was shown to be effective in mouse and human cells 
in 2013 (32).
There has been a veritable explosion in genome editing 
research, with CRISPR/Cas9 regarded as the system with the 
most flexibility(33).  Since 2012, articles on genome editing 
have increased from 12,300 to 39,600 (Table 5), demonstrat-
ing their applicability to any system, human, animal, or plant, 
alongside their bacterial origins (34,35).  An alternative to the 
use of Cas9 nuclease is Cpf1, which requires only a single crR-
NA for targeting, uses smaller crRNAs, recognises a PAM 5’ 
rather than 3’ of the target site to generate sticky ends and may 
provide specificity enhancements over Cas9 (24).  This may 
prove to be CRISPR/Cas9 nucleases biggest competitor (36,37).
Although not without difficulties, principally surrounding 
the frequency of off-target events, where unintended cutting at 
off-site targets may occur (24), precision genome manipulation 
with CRISPR/Cas9 is becoming commonplace in any organism 
in ways which were not previously feasible (38), and may be 
used to investigate control of any biological process (39). This 
includes designing effective gene drives, able to rapidly spread 
through insect populations in only a few generations (40,41) 
and Cas9 nuclease triggered chain ablation gene drive brakes, 
as a potential counterbalancing evolutionary force (42). Poten-
tial applications include curbing the spread of malaria, or of 
Zika virus.  Applications in precision medicine have included 
reduced HIV loading or viral progenome elimination (43). Ge-
netic repair of faulty retinitis pigmentosa genes in inducible 
pluripotent stem cells, affecting 1 in 4,000 people, demonstrates 
how genetically corrected stem cells can be used for transplan-
tation purposes in retinal disease (44). 
The most controversial developments in genome editing 
have surrounded the application of human genome editing. 
A recent International Summit on Human Gene Editing, or-
ganised by the US National Academy of Sciences, US Nation-
al Academy of Medicine, the Royal Society and the Chinese 
Academy of Sciences (2015) discussed the potential and possi-
ble pitfalls of gene editing in humans (45). The Panel ultimately 
differentiated between  four categories: basic and preclinical 
research, where modified cells should not be used to establish 
pregnancies; somatic cell clinical use, where proposed  stud-
ies could affect only individuals they may be appropriately 
regulated within existing frameworks; and potential germline 
clinical uses, where alterations in gamete or embryos are pos-
sible.  Germline clinical uses were considered higher risk and 
because of their potential to alter gene pools for future gener-
ations, should not be undertaken until relevant safety, efficacy, 
ethical and societal issues have been resolved (45).  Chinese 
scientists have been engaged in two partially successful trials of 
CRISPR/Cas9 genome editing.  Liang et al. (46) used CRISPR/
Cas9 to edit beta-globin genes in tripronuclear (3PN) zygotes. 
The triploid nature of these embryos rendered them non-via-
ble.  The gene editing process was however, inefficient, and ed-
ited embryos were mosaic, with off-target cleavage effects also 
Table 4. Genome Editing Tools
Editing Tool Mechanism
Zinc Finger Nucleases Zinc finger DNA-binding domain fused 
to DNA cleavage nuclease domain, 
recognising 9-18 bp sequence (22)
TALENS Fusion specific TAL-effector DNA bind-
ing domain with DNA cleavage nucle-
ase domain, e.g. Fok1 (23)
CRISPR/Cas9 Two-part guide RNA binds to target se-
quence and with Cas 9 nuclease cleaves 
double stranded DNA (20)
CRISPR/Cpf1 Single guide RNA combines with Cpf1  
nuclease to target sequence for cutting 
and production of sticky ends (24)







Source: Google Scholar, accessed 02.01.2017.
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apparent. An endogenous alternative globin gene (delta-globin, 
HBD) competed with injected oligos as the repair template and 
led to unanticipated mutations (47). Kang et al. (48) injected 
Cas9 mRNA, guide RNA and donor DNA for the naturally 
occurring CCR5∆32 alleles into early, non-viable human 3PN 
embryos. The CCR5∆32 allele renders cells resistant to HIV 
infection, by preventing HIV particles from entering T cell tar-
gets. Only 4 of 26 human embryos were modified successfully, 
from a total of 213 fertilized human eggs.  Both of these stud-
ies emphasised the inefficiency of human embryo gene editing 
and that further understanding of how to limit off-target effects 
in particular, would be needed before proceeding to implanta-
tion or clinical applications (49).  Further trials are underway 
in the United States and China.  Animal science applications 
have also expanded rapidly, including modelling of veterinary 
diseases and the production of supermuscled pigs, by South 
Korean and Chinese scientists (38). Development of the su-
permuscled pigs used TALEN to introduce a mutation into the 
MSTN gene of pig foetal cells, disrupting myostatin inhibition 
of muscle growth.  Thirty-two gene edited piglets with twice 
the lean meat content of unedited pigs were produced, but only 
13/32 reached 8 months old, with only a single piglet consid-
ered healthy (50).
Developments in gene editing are not just limited to human 
and animal systems, but are coming to fruition in plant bio-
technology too.  Rapidly increasing world population, expected 
to reach 9.7 billion by 2050 (51) and increasingly unpredict-
able climate variation will place ever greater demands on global 
food production (52). Genome editing has a huge part to play 
in meeting this need, particularly if edited products containing 
only deletions or self-cloned additions or substitutions are clas-
sified as not requiring regulation, as in the USA (53), or stalled 
in the European Union regulatory impasse (54). This dichot-
omy rests on whether product or process based regulation is 
applied globally, and whether, in the case of the EU, crop plants 
without any additional DNA sequences are considered within 
the scope of the increasingly outdated EU Directive 2002/219. 
Plants with no additional DNA, or containing only native ge-
nome substitutions, are indistinguishable from parental lines at 
the DNA sequence level.   They are likely to proceed through 
GMO regulations rapidly, once EU and possibly member-na-
tion policies, have been determined.  In contrast, an increasing 
range of genome edited plants have been considered as not re-
quiring US Dept. of Agriculture oversight (not requiring reg-
ulation). 
At least five genome edited crop plants have been produced, 
using Zinc Finger Nuclease, TALENS and CRISPR/Cas 9 nu-
clease technologies.  USDA determined that Dow AgroSci-
ence’s ZFN-12 phytate reduced maize was not a regulated ar-
ticle, being produced by ZFN induced partial deletions of the 
IPK 1 gene (55).  TALEN has been used to simultaneously edit 
three homeoalleles in hexaploid bread wheat for broad spec-
trum resistance to powdery mildew (56), whilst Calyxt’s mil-
dew resistant ‘MLO-KO’ wheat, produced using TALEN has 
been determined to be outwith USDA oversight (57). CRISPR/
Cas9 has provided the majority of crop plant genome editing 
applications(58).  Penn State’s Yinong Yang has developed mil-
dew resistant white button mushrooms (Agaricus bisporus) in 
which CRISPR/Cas9 has been used to delete several 1-14 nu-
cleotide regions of the polyphenol oxidase gene, responsible for 
browning, has led not only to non-browning but also to en-
hanced shelf life. These mushrooms were judged to be ‘with-
out need for USDA oversight’ and are thus available for com-
mercial scale release (59,60). DuPont Pioneer have obtained a 
similar positive determination for their ARGOS8 waxy maize, 
gene edited using the native maize GOS2 promoter. ARGOS8 
is a negative regulator of ethylene responses.  DuPont Pioneer’s 
waxy maize provides 5 bushels/acre grain yield advantage un-
der flowering stress conditions and no yield penalty under well 
watered conditions (61). Du Pont Pioneer ‘Waxy Maize’ should 
reach the marketplace within five years (62,63). 
Perhaps the most advanced example of gene edited crop 
plants comes from Cibus’ sulfonyl urea herbicide tolerant cano-
la 5715 (oil seed rape, Brassica napus) which does not require 
USDA oversight. By using CRISPR/Cas9 nuclease, a wide range 
of broadleaf weed control has been achieved.   50,000 acres of 
Canola 5715 were planted in the USA in 2014, with further 
scale up for USA commercial release in 2016 and planned re-
lease for Canada in 2017(Fig. 2; 64). Canada adopts a product 
based regulatory approach similar to that of the USA. Cibus is 
also developing similar products in flax, for 2022 release. 
There is no doubt that gene editing, led by CRISPR/Cas9 and 
probably CRISPR/Cpf1, will have a fundamental role to play in 
future human somatic and germline cell manipulations (38). 
Insights into the editing process, reducing off-target effects and 
unintended mutations, gene regulation, imaging and epigene-
tic marking via sequence specific modifications will contribute 
to our future understanding in biomedicine, and agriculture 
(22).  Ownership of the intellectual property rights surround-
ing CRISPR, Cas 9 nuclease and other gene editing tools are 
Figure 2: Sulphonyl-Urea herbicide tolerant canola 5715 seed 
packaging. Source: Cibus.com
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currently ill-defined, with at least three groups claiming owner-
ship. This may, at least in the short term, limit commercial and 
clinical applications (65).
Mitochondrial Replacement Therapy and 
‘3-Parent’ Babies
Although not currently regarded as either genome or gene ed-
iting, the potential to explore mitochondrial replacement to 
overcome mitochondrial disease risk though maternal inheri-
tance is being studied intensively.  Mitochondrial DNA, which 
harbours only 37 genes and makes up 0.1% of total genomic 
DNA, is extensively involved in cell energy production. mtDNA 
mutations can cause severe debilitation in children, or prove 
fatal due to energy system defects or faulty neural system de-
velopment. Mitochondrial replacement, for example through 
transferring nuclei from defective maternal egg cells to donor 
egg cells lacking known mitochondrial mutations could allow 
parents with maternal rare mitochondrial diseases to produce 
healthy babies.  Zhang et al. announced the world’s first ‘3-Par-
ent’ baby, (66) with the successful birth followed spindle nucle-
ar transfer, in which the nucleus was removed from a maternal 
egg and inserted into an enucleated donor egg, which was then 
fertilised in vitro.  This avoided the need to waste any human 
embryos (67). Five embryos were created, one of which devel-
oped normally and proceded to implantation and live birth of 
a boy. Mitochondrial analysis revealed that < 1% of mitochon-
dria carried the Leigh Syndrome defective gene, compared with 
the 13% considered necessary for likely phenotypic expression. 
Kang et al. (68) have replaced mitochondria in human oo-
cytes carrying pathogenic mitochondrial DNA mutations, to 
investigate how mitochondrial replacement therapies can po-
tentially prevent mother to child mtDNA disease transmission. 
After mitochondrial replacement, the eggs were fertilised, and 
healthy embryos taken to the blastocyst stage (69). As yet, 
‘3-Parent’ Babies are only legally permitted in the UK, as the 
Human Fertilisation & Embryology will permit cautious use of 
mitochondrial donation in treatment (70).   Following the birth 
of the Mexican baby boy, it is likely that other countries will 
advance consideration of the appropriateness of mitochondrial 
treatments being allowed to proceed to implantation and term 
birth.  This approach is however, not without controversy, in-
cluding whether or not the egg donor will have any legal rights 
or obligations. In the UK Parliamentary approved situation, for 
example, egg donors have no such rights whatsoever.  
Controversy therefore surrounds aspects of genome edit-
ing and the application of mitochondrial replacement therapy 
through three parent babies.  The years to come will see resolu-
tion of questions such as whether genome editing is classified as 
genetic modification in different regions of the world, together 
with ethical, moral and legal questions surrounding three par-
ent babies.  What is clear, however, is that further advances in 
genomics and genome editing will continue to advance the art 
of what is technically possible, whilst leaving society to decide 
whether what can be achieved should be applied.   
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